Colorcon acquires Paulaur Corporation’s pharmaceutical sugar spheres business
The addition of the Paulaur products complements Colorcon’s Suglets Sugar Spheres product line and enhances Colorcon’s position as a leading global supplier of sugar spheres for the development of multiparticulate dosages.
Colorcon has announced the acquisition of the Pharmaceutical Sugar Spheres product line from Paulaur Corporation, a manufacturer of specialty sugar‐based ingredients located in Cranbury, New Jersey.
The addition of the Paulaur products complements Colorcon’s Suglets Sugar Spheres product line and enhances Colorcon’s position as a leading global supplier of sugar spheres for the development of multiparticulate dosages. The agreement is specific to Paulaur sugar spheres sold into the pharmaceutical and nutritional segments globally.
Colorcon provides speciality excipients for pharmaceutical and nutraceutical applications worldwide, and has identified strong synergies between the multiparticulate and film coating businesses. Colorcon is well‐positioned to serve pharmaceutical and nutraceutical spheres customers thanks to its range of immediate, delayed and extended release coatings and previous investment in the multiparticulate business.
Pankaj Rege, General Manager for Colorcon Manufactured Products explains: “There is strong demand in the industry for a supplier who offers high quality product, application and formulation support with a multi‐facility business continuity plan. This acquisition complements Colorcon’s existing investment in its people, capabilities, and organization, which have consistently delivered superior products and services to Colorcon’s pharmaceutical and dietary supplement customers.”
Mitchell Stefaniak, Vice President and Chief Financial Officer of Paulaur Corporation, commented that “Paulaur had made the decision to leave the pharmaceutical and nutraceutical spheres arena to concentrate on our fast‐growing food and confectionary business. At the same time, we wanted to insure that our pharmaceutical and nutraceutical spheres customers could be assured of a continued availability of quality product. The sale to Colorcon provides our customers with just such a supplier.”
Martti Hedman, Colorcon’s CEO states: “Paulaur’s pharmaceutical sugar spheres business is an exciting strategic acquisition for Colorcon. This announcement comes at the end of another strong year for us, with growth across all business areas. Colorcon views this agreement as an opportunity to expand Colorcon's sugar spheres business and leverage our global distribution, technical service, and sales infrastructure."
Colorcon provides a full range of products and services for solid oral dosage formulations and continues to see growth in multiparticulate dosages forms, especially for geriatric and pediatric populations. Due to this agreement, Colorcon and Paulaur customers stand to benefit with direct access to products, technical service and support from Colorcon.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance